论文部分内容阅读
目的:比较环磷酰胺-西艾克-吡柔比星-泼尼松(Cyclophosphamidum-Vindesine-Tetrahydropyranyl-Prednisone,CVTP)联合化疗方案对初治和复治、难治恶性淋巴瘤的临床疗效。方法:按照化疗史将102例恶性淋巴瘤患者分为初治组59例和复治难治组43例,两组患者均给予CVTP联合化疗方案治疗,比较两组化疗效果、外周血淋巴细胞亚群、毒副反应差别。结果:初治组患者部分缓解(partial remission,PR)率和总有效率(overall response rate,ORR)均显著高于对复治难治组,差异具有统计学意义(P<0.05);初治组患者治疗后CD3~+、CD4~+、CD4~+/CD8~++、NK细胞含量均显著高于复治难治组,CD8~+水平显著低于复治难治组,差异具有统计学意义(P<0.05);初治组患者化疗期间白细胞下降、血红蛋白下降、血小板减少、恶心呕吐发生率均显著低于复治难治组,差异具有统计学意义(P<0.05)。结论:CVTP联合化疗方案治疗初治恶性淋巴瘤近期疗效优于复治难治患者。
Objective: To compare the clinical effects of cyclophosphamide-Vindesine-Tetrahydropyranyl-Prednisone (CVTP) and chemotherapy regimens in the treatment of newly diagnosed and refractory and refractory lymphoma. Methods: According to the chemotherapy history, 102 patients with malignant lymphoma were divided into initial treatment group (n = 59) and retreatment refractory group (n = 43). CVTP combined with chemotherapy was given to both groups. The effects of chemotherapy, peripheral blood lymphocyte Group, differences in side effects. Results: The partial remission (PR) rate and overall response rate (ORR) of the newly diagnosed group were significantly higher than those of the refractory and refractory group (P <0.05) After treatment, the levels of CD3 ~ +, CD4 ~ +, CD4 ~ + / CD8 ~ + + and NK cells in the treatment group were significantly higher than those in the refractory and refractory group, and the levels of CD8 ~ + were significantly lower than those in the refractory and refractory group (P <0.05). The incidence of leukopenia, hemoglobin decrease, thrombocytopenia and nausea and vomiting in patients in newly diagnosed group were significantly lower than those in refractory and refractory patients (P <0.05). Conclusion: The efficacy of CVTP combined with chemotherapy in the treatment of primary malignant lymphoma is better than that of refractory refractory patients.